Topics

Bayer’s tumor-agnostic cancer drug gets European nod

15:37 EDT 23 Sep 2019 | MedCity News

Bayer said Monday that the European Medicines Agency had approved Vitrakvi for NTRK fusion-positive cancers. The drug won U.S. Food and Drug Administration accelerated approval in November.

Original Article: Bayer’s tumor-agnostic cancer drug gets European nod

NEXT ARTICLE

More From BioPortfolio on "Bayer’s tumor-agnostic cancer drug gets European nod"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...